Neumora Therapeutics
Surveying great inventors and businesses
Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company. We are excited to be in business with you — email us at info@axialvc.com
Neumora Therapeutics is a clinical-stage biotech company focused on developing novel therapies for the large, underserved market of neuropsychiatric and neurodegenerative disorders. Founded in 2019, Neumora has rapidly scaled its pipeline to 7 clinical and preclinical programs targeting novel mechanisms of action, reflecting its mission to take a fundamentally different R&D approach compared to the historical lack of innovation in neuroscience.
Neumora’s lead asset, navacaprant, is an oral kappa opioid receptor antagonist positioned to address major depressive disorder (MDD), a prevalent condition affecting over 20M diagnosed patients in the US alone. As a novel MoA compared to standard-of-care SSRIs/SNRIs, navacaprant could provide a much-needed alternative option in an area of high unmet need. Navacaprant is entering pivotal Phase 3 in 2H2023, with initial data expected in 2H2024. Beyond MDD, additional neuropsychiatric indications are being explored.
Behind navacaprant, Neumora has built a broad pipeline of earlier-stage clinical and preclinical programs targeting other novel CNS mechanisms across anxiety, psychosis, cognition, neuroinflammation, and neurodegeneration. This includes NMRA-511 (V1aR antagonist), NMRA-266 (M4 PAM), and preclinical programs for NMDA modulation, TDP-43, NLRP3, and GCase activation. The pipeline exhibits Neumora’s intent to establish leadership in neuroscience R&D innovation. Multiple clinical trials and data readouts are expected over the next 12-18 months.
Neumora’s strategy centers on sustaining pipeline momentum in advancing its lead asset navacaprant towards commercialization while allocating capital efficiently across emerging mid-stage programs and preclinical portfolio. This is enabled by its precision medicine capabilities and IP position around novel CNS targets. accessing the necessary funding to support its ambitious goals will be key.
An experienced leadership team and prominent investors help set the stage for success in executing Neumora’s neuroscience mission. The team combines proven company builders, dealmakers, and neuroscience drug developers, while backers include leading biotech VC firms. Over $600M has been raised to date. Despite the promise, Neumora faces substantial risks typical of biotech and neuroscience focused companies. The company’s diverse clinical and preclinical programs carry development delays or failures. As a novel player in CNS, clinical or commercial success is far from guaranteed, while competition remains strong from larger players from Neurocrine to Pfizer/Cerevel.
Neumora represents an emerging neuroscience company with ambitious goals of delivering transformative new CNS therapies. Backed by strategic investors and led by experienced drug developers, Neumora has quickly built a broad pipeline centered around its lead navacaprant program. Realizing the full neuroscience opportunity relies on prudent capital allocation decisions and achieving clinical success over the next 3-5 years.
